Treatment of Multiple Sclerosis
Authors:
- Anne CrossACAnne Cross
- Claire RileyCRClaire Riley
- 1 August 2022
- journal article
- review article
- Published by Wolters Kluwer Health in Continuum
- Vol. 28 (4) , 1025-1051
Abstract
, efficacy, and safety considerations for each of the therapeutic classes. RECENT FINDINGS The armamentarium of immunotherapies has grown rapidly, to encompass 19 US Food and Drug Administration (FDA)-approved immunotherapies available in 2021, which are addressed in the review. The coronavirus pandemic that began in 2020 underscored existing concerns regarding vaccine efficacy in those treated with immune-suppressing immunotherapies, which are also addressed here. SUMMARY By choosing a treatment strategy before exploring the individual medications, patients and providers can focus their efforts on a subset of the therapeutic options. Although the mechanisms of action, routes of administration, efficacy, safety, and tolerability of the described agents and classes differ, all are effective in reducing relapse frequency in multiple sclerosis (MS), with most also showing a reduction in the accumulation of neurologic disability. These powerful effects are improving the lives of people with MS. Pharmacovigilance is critical for the safe use of these immune-modulating and -suppressing agents, and vaccine efficacy may be reduced by those with immune-suppressing effects....Keywords
This publication has 76 references indexed in Scilit:
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple SclerosisNew England Journal of Medicine, 2010
- Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple SclerosisNew England Journal of Medicine, 2010
- A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple SclerosisNew England Journal of Medicine, 2010
- Measures in the first year of therapy predict the response to interferon β in MSMultiple Sclerosis Journal, 2009
- A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple SclerosisNew England Journal of Medicine, 2006
- Natalizumab plus Interferon Beta-1a for Relapsing Multiple SclerosisNew England Journal of Medicine, 2006
- Increases in soluble VCAM‐1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon β‐1bAnnals of Neurology, 1997
- Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria.Journal of Neurology, Neurosurgery & Psychiatry, 1997
- Interferon beta induces interleukin‐10 expression: Relevance to multiple sclerosisAnnals of Neurology, 1996
- Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosisNeurology, 1995